A Phase 2 interventional study of Zanubrutinib in Marginal Zone Lymphoma and MZL, sponsored by BeiGene. Completed at 31 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Lymphoma, B-Cell, Marginal Zone with a site in Australia — 6 open to participants now, 13 under way, 3 of them phase 3. Lymphoma, B-Cell, Marginal Zone · Australia.
Among the 36 studies in Lymphoma, B-Cell, Marginal Zone with a site in Australia, this one is the 29th largest by enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2019, is one of 7 in phase 2, and was the 15th registered.
875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.
Browse Lymphoma, B-Cell, Marginal Zone studies →6 of the 36 studies in Lymphoma, B-Cell, Marginal Zone with a site in Australia are open now. Recruiting first, the newest first:
Taiho Oncology, Inc. · Sites in Australia, United States, France and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in Australia, United States, Canada and 9 more countries
Ages 18+
ModeX Therapeutics, An OPKO Health Company · Sites in Australia, Israel, Spain
Ages 18+
Regeneron Pharmaceuticals · Sites in Australia, United States, Austria and 15 more countries
Ages 18+
CRISPR Therapeutics AG · Sites in Australia, United States
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 15 · Phase 3 11
First in 1997; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 40 across 681 interventional studies indexed under Lymphoma, B-Cell, Marginal Zone.
Median enrollment 120 across the 35 interventional studies, 174 across the 1 observational. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 9 studies filed under Lymphoma, B-Cell, Marginal Zone — fewer than ten, so there is no comparison to draw.
3 of the studies in Lymphoma, B-Cell, Marginal Zone with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06667687AbbVieStudy to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma | 2027-01 |
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
| NCT07101328Eli Lilly and CompanyA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Lymphoma, B-Cell, Marginal Zone with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent
Drug: Zanubrutinib
Zanubrutinib at a dose of 160 mg orally twice a day (BID)
Also known as: BGB-3111, Brukinsa
Overall Response Rate (ORR) by Independent Review Committee (IRC) Assessment
ORR is defined as the percentage of participants with complete or partial response as the best overall response, as determined by an IRC using the Lugano Classification
Time frame: Up to approximately 3 years and 2.5 months
ORR by Investigator Assessment
ORR is defined as the percentage of participants with complete or partial response as the best overall response, as determined by the investigator using the Lugano Classification.
Time frame: Up to approximately 3 years and 2.5 months
ORR by IRC Assessment Using Positron Emission Tomography-Computed Tomography (PET-CT)
ORR is defined as the percentage of participants with complete and partial response as the best overall response, as determined by an IRC using PET-CT assessment data for participants with fluorodeoxyglucose (FDG)-avid disease
Time frame: Up to approximately 3 years and 2.5 months
Progression-free Survival (PFS) by Investigator Assessment
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using Lugano Classification
Time frame: Up to approximately 3 years and 2.5 months
PFS Event-Free Rate by Investigator Assessment
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for PFS at 24 months with 95% confidence intervals estimated using Greenwood's formula.
Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
PFS by IRC Assessment
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by an IRC using Lugano Classification
Time frame: Up to approximately 3 years and 2.5 months
PFS Event-Free Rate by IRC Assessment
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for PFS at 24 months with 95% confidence intervals estimated using Greenwood's formula.
Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Overall Survival (OS)
OS is defined as the time from first study drug administration to the date of death due to any cause
Time frame: Up to approximately 3 years and 2.5 months
OS Event-Free Rate
OS is defined as the time from first study drug administration to the date of death due to any cause. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for OS at 24 months with 95% confidence intervals estimated using Greenwood's formula.
Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Duration of Response (DOR) by Investigator Assessment
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification.
Time frame: Up to approximately 3 years and 2.5 months
DOR Event-Free Rate by Investigator Assessment
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 24 months with 95% confidence intervals estimated using Greenwood's formula.
Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
DOR by IRC Assessment
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using Lugano Classification.
Time frame: Up to approximately 3 years and 2.5 months
DOR Event-Free Rate by IRC Assessment
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 24 months with 95% confidence intervals estimated using Greenwood's formula.
Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Time to Treatment Failure (TTF)
TTF is defined as the time from study treatment start to the date of discontinuation of study drug due to any reason.
Time frame: Up to approximately 3 years and 2.5 months
TTF Event-Free Rate
TTF is defined as the time from study treatment start to the date of discontinuation of study drug due to any reason. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for TTF at 24 months with 95% confidence intervals estimated using Greenwood's formula.
Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Time to Next Line of Therapy
Time to next line of therapy is defined as the time from study treatment start to the start of the first subsequent therapy for MZL
Time frame: Up to approximately 3 years and 2.5 months
Time to Next Line of Therapy Event-Free Rate
Time to next line of therapy is defined as the time from study treatment start to the start of the first subsequent therapy for MZL. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for time to next line of therapy at 24 months with 95% confidence intervals estimated using Greenwood's formula.
Time frame: Up to 3 years and 2.5 months after first participant enrolled; Month 24 reported
Time to Response (TTR) by Investigator Assessment
TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better) as assessed by the investigator using Lugano Classification
Time frame: Up to approximately 3 years and 2.5 months
TTR by IRC Assessment
TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better), as assessed by the IRC using Lugano Classification.
Time frame: Up to approximately 3 years and 2.5 months
Change From Baseline in EuroQol 5-dimension 5-level (EQ-5D-5L) Visual Analogue Score (VAS)
Mean change from baseline in EQ-5D-5L VAS. The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' Positive change from baseline indicates improved health.
Time frame: Baseline to Cycle 30 (28 days per cycle)
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status
Mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes global health status and quality of life questions related to their overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a positive score from baseline indicating improved health.
Time frame: Baseline to Cycle 30 (28 days per cycle)
Number of Participants With Adverse Events
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory tests, physical exams, and vital signs
Time frame: From first dose to 30 days after last dose of study drug (Up to approximately 3 years and 2.5 months)
Area Under the Curve From Time 0 to 6 Hours (AUC0-6)
Time frame: Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
Apparent Oral Clearance (CL/F) of Zanubrutinib
Time frame: Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
Maximum Observed Concentration (Cmax)
Time frame: Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
Elimination Half Life (t1/2)
Time frame: Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
This study was conducted at 31 study centers in 9 countries.
| Milestone | Zanubrutinib |
|---|---|
| Started | 68 |
| Completed | 51 |
| Not completed | 17 |
| Withdrew: Death | 13 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Physician decision | 1 |
ORR is defined as the percentage of participants with complete or partial response as the best overall response, as determined by an IRC using the Lugano Classification
| Percentage of participants | Zanubrutinib |
|---|---|
| Overall Response Rate (ORR) by Independent Review Committee (IRC) Assessment | 68.2 (55.56 to 79.11) |
ORR is defined as the percentage of participants with complete or partial response as the best overall response, as determined by the investigator using the Lugano Classification.
| Percentage of participants | Zanubrutinib |
|---|---|
| ORR by Investigator Assessment | 75.8 (63.64 to 85.46) |
ORR is defined as the percentage of participants with complete and partial response as the best overall response, as determined by an IRC using PET-CT assessment data for participants with fluorodeoxyglucose (FDG)-avid disease
| Percentage of participants | Zanubrutinib |
|---|---|
| ORR by IRC Assessment Using Positron Emission Tomography-Computed Tomography (PET-CT) | 69.5 (56.13 to 80.81) |
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using Lugano Classification
| Months | Zanubrutinib |
|---|---|
| Progression-free Survival (PFS) by Investigator Assessment | NA (16.5 to NA) |
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for PFS at 24 months with 95% confidence intervals estimated using Greenwood's formula.
| Percentage of participants | Zanubrutinib |
|---|---|
| PFS Event-Free Rate by Investigator Assessment | 57.9 (44.83 to 68.86) |
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by an IRC using Lugano Classification
| Months | Zanubrutinib |
|---|---|
| PFS by IRC Assessment | NA (27.6 to NA) |
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for PFS at 24 months with 95% confidence intervals estimated using Greenwood's formula.
| Percentage of participants | Zanubrutinib |
|---|---|
| PFS Event-Free Rate by IRC Assessment | 70.9 (57.20 to 80.95) |
OS is defined as the time from first study drug administration to the date of death due to any cause
| Months | Zanubrutinib |
|---|---|
| Overall Survival (OS) | NA (NA to NA) |
OS is defined as the time from first study drug administration to the date of death due to any cause. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for OS at 24 months with 95% confidence intervals estimated using Greenwood's formula.
| Percentage of participants | Zanubrutinib |
|---|---|
| OS Event-Free Rate | 85.9 (74.7 to 92.4) |
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification.
| Months | Zanubrutinib |
|---|---|
| Duration of Response (DOR) by Investigator Assessment | NA (22.1 to NA) |
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 24 months with 95% confidence intervals estimated using Greenwood's formula.
| Percentage of participants | Zanubrutinib |
|---|---|
| DOR Event-Free Rate by Investigator Assessment | 60.8 (44.8 to 73.6) |
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using Lugano Classification.
| Months | Zanubrutinib |
|---|---|
| DOR by IRC Assessment | NA (25.0 to NA) |
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using Lugano Classification. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 24 months with 95% confidence intervals estimated using Greenwood's formula.
| Percentage of participants | Zanubrutinib |
|---|---|
| DOR Event-Free Rate by IRC Assessment | 72.9 (54.4 to 84.9) |
TTF is defined as the time from study treatment start to the date of discontinuation of study drug due to any reason.
| Months | Zanubrutinib |
|---|---|
| Time to Treatment Failure (TTF) | 27.8 (14.7 to NA) |
TTF is defined as the time from study treatment start to the date of discontinuation of study drug due to any reason. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for TTF at 24 months with 95% confidence intervals estimated using Greenwood's formula.
| Percentage of participants | Zanubrutinib |
|---|---|
| TTF Event-Free Rate | 53.0 (40.4 to 64.2) |
Time to next line of therapy is defined as the time from study treatment start to the start of the first subsequent therapy for MZL
| Months | Zanubrutinib |
|---|---|
| Time to Next Line of Therapy | NA (NA to NA) |
Time to next line of therapy is defined as the time from study treatment start to the start of the first subsequent therapy for MZL. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for time to next line of therapy at 24 months with 95% confidence intervals estimated using Greenwood's formula.
| Percentage of participants | Zanubrutinib |
|---|---|
| Time to Next Line of Therapy Event-Free Rate | 74.5 (61.7 to 83.6) |
TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better) as assessed by the investigator using Lugano Classification
| Months | Zanubrutinib |
|---|---|
| Time to Response (TTR) by Investigator Assessment | 2.79 (1.7 to 16.6) |
TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better), as assessed by the IRC using Lugano Classification.
| Months | Zanubrutinib |
|---|---|
| TTR by IRC Assessment | 2.79 (1.7 to 11.1) |
Mean change from baseline in EQ-5D-5L VAS. The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' Positive change from baseline indicates improved health.
| Score on a scale | Zanubrutinib |
|---|---|
| Cycle 3 | 1.0 ± 18.18 |
| Cycle 6 | 2.2 ± 15.78 |
| Cycle 9 | 0.2 ± 16.28 |
| Cycle 12 | 2.8 ± 16.15 |
| Cycle 18 | 5.6 ± 17.68 |
| Cycle 24 | 5.8 ± 15.24 |
| Cycle 30 | 1.6 ± 18.15 |
Mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients and includes global health status and quality of life questions related to their overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Answers are converted to a score of 0 to 100, with a positive score from baseline indicating improved health.
| Score on a scale | Zanubrutinib |
|---|---|
| Cycle 3 | 7.471 ± 19.5396 |
| Cycle 6 | 7.823 ± 15.8121 |
| Cycle 9 | 5.382 ± 20.0833 |
| Cycle 12 | 7.143 ± 17.3216 |
| Cycle 18 | 10.677 ± 18.4811 |
| Cycle 24 | 9.286 ± 19.2561 |
| Cycle 30 | 6.250 ± 20.4910 |
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory tests, physical exams, and vital signs
| Participants | Zanubrutinib |
|---|---|
| At least one TEAE | 68 |
| At least one SAE | 30 |
| Hour*ng/mL | Zanubrutinib |
|---|---|
| Area Under the Curve From Time 0 to 6 Hours (AUC0-6) | 868.0 ± 304.3 |
| Liters/hour | Zanubrutinib |
|---|---|
| Apparent Oral Clearance (CL/F) of Zanubrutinib | 215.3 ± 114.8 |
| nanograms/milliliter | Zanubrutinib |
|---|---|
| Maximum Observed Concentration (Cmax) | 315.5 ± 120.2 |
| Hours | Zanubrutinib |
|---|---|
| Elimination Half Life (t1/2) | 1.2 (0.8 to 2.7) |
Collected over From first dose to 30 days after last dose of study drug (Up to approximately 3 years and 2.5 months). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zanubrutinib | 13/68 (19.1%) | 30/68 (44.1%) | 61/68 (89.7%) |
| Event | Zanubrutinib |
|---|---|
| COVID-19 pneumoniaInfections and infestations | 4/68 |
| PyrexiaGeneral disorders | 3/68 |
| PneumoniaInfections and infestations | 3/68 |
| FallInjury, poisoning and procedural complications | 2/68 |
| SyncopeNervous system disorders | 2/68 |
| AnaemiaBlood and lymphatic system disorders | 1/68 |
| PancytopeniaBlood and lymphatic system disorders | 1/68 |
| Angina pectorisCardiac disorders | 1/68 |
| Atrial fibrillationCardiac disorders | 1/68 |
| Atrial flutterCardiac disorders | 1/68 |
| Event | Zanubrutinib |
|---|---|
| ContusionInjury, poisoning and procedural complications | 16/68 |
| DiarrhoeaGastrointestinal disorders | 15/68 |
| ConstipationGastrointestinal disorders | 12/68 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/68 |
| Upper respiratory tract infectionInfections and infestations | 9/68 |
| Abdominal painGastrointestinal disorders | 8/68 |
| PyrexiaGeneral disorders | 8/68 |
| Back painMusculoskeletal and connective tissue disorders | 8/68 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/68 |
| NauseaGastrointestinal disorders | 7/68 |
| Age, Continuous(Years) | Zanubrutinib |
|---|---|
| Mean | 67.9 ± 11.41 |
| Sex: Female, Male(Participants) | Zanubrutinib |
|---|---|
| Female | 32 |
| Male | 36 |
| Ethnicity (NIH/OMB)(Participants) | Zanubrutinib |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 58 |
| Unknown or Not Reported | 10 |
| Race/Ethnicity, Customized(Participants) | Zanubrutinib |
|---|---|
| Asian | 13 |
| White | 40 |
| Multiple | 2 |
| Other | 1 |
| Unknown | 1 |
| Not Reported | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Feb 2019 to primary completion in May 2022, 38 months.
Of 113 phase 2 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 38 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanubrutinib
Lymphoma, B-Cell, Marginal Zone →